&Partners Purchases 9,077 Shares of GSK plc (NYSE:GSK)

&PARTNERS lifted its position in GSK plc (NYSE:GSK - Free Report) by 133.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,876 shares of the pharmaceutical company's stock after purchasing an additional 9,077 shares during the quarter. &PARTNERS's holdings in GSK were worth $611,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Register Financial Advisors LLC bought a new stake in GSK during the first quarter valued at approximately $31,000. Richardson Financial Services Inc. purchased a new stake in shares of GSK during the 4th quarter valued at $40,000. Newbridge Financial Services Group Inc. bought a new stake in shares of GSK during the 1st quarter worth $49,000. Triad Wealth Partners LLC purchased a new position in GSK in the second quarter worth $49,000. Finally, Jones Financial Companies Lllp increased its stake in GSK by 23.1% in the fourth quarter. Jones Financial Companies Lllp now owns 1,633 shares of the pharmaceutical company's stock valued at $61,000 after acquiring an additional 306 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. UBS Group lowered GSK from a "buy" rating to a "neutral" rating in a research note on Monday, July 8th. Citigroup upgraded GSK to a "strong-buy" rating in a research report on Monday, June 24th. The Goldman Sachs Group began coverage on shares of GSK in a research report on Thursday, May 30th. They set a "neutral" rating and a $47.00 price target on the stock. Jefferies Financial Group lifted their price target on shares of GSK from $52.50 to $53.00 and gave the stock a "buy" rating in a research note on Tuesday, July 2nd. Finally, Argus raised shares of GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, GSK currently has an average rating of "Buy" and an average target price of $50.00.

GSK Trading Up 1.6 %

GSK stock traded up $0.68 during trading hours on Friday, reaching $42.63. The company had a trading volume of 3,780,536 shares, compared to its average volume of 3,539,795. The firm has a market cap of $88.35 billion, a price-to-earnings ratio of 15.45, a P/E/G ratio of 1.32 and a beta of 0.64. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.58. The company has a 50-day moving average price of $39.82 and a 200 day moving average price of $41.51.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be paid a $0.3843 dividend. The ex-dividend date of this dividend is Friday, August 16th. This is a boost from GSK's previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a dividend yield of 3.61%. GSK's dividend payout ratio (DPR) is presently 54.71%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.